Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -69.95 Billion KRW | -651.9% |
| 2022 | 12.8 Billion KRW | 22.12% |
| 2021 | 10.48 Billion KRW | -24.83% |
| 2020 | 13.95 Billion KRW | 822.77% |
| 2019 | -1.93 Billion KRW | -133.82% |
| 2018 | -825.58 Million KRW | 43.36% |
| 2017 | -1.45 Billion KRW | -489.24% |
| 2016 | -247.37 Million KRW | 71.45% |
| 2015 | -866.3 Million KRW | 83.81% |
| 2014 | -5.35 Billion KRW | 60.5% |
| 2013 | -13.55 Billion KRW | 17.34% |
| 2012 | -16.39 Billion KRW | -2097.08% |
| 2011 | 820.86 Million KRW | -35.29% |
| 2010 | 1.26 Billion KRW | -68.2% |
| 2009 | 3.98 Billion KRW | 196.25% |
| 2008 | -4.14 Billion KRW | -138.49% |
| 2007 | -1.73 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -11.31 Billion KRW | 5.64% |
| 2024 Q1 | -11.99 Billion KRW | 70.56% |
| 2023 Q2 | -12.85 Billion KRW | -577.65% |
| 2023 Q3 | -14.36 Billion KRW | -11.72% |
| 2023 Q4 | -40.72 Billion KRW | -183.48% |
| 2023 FY | -70.69 Billion KRW | -651.9% |
| 2023 Q1 | -1.89 Billion KRW | -171.87% |
| 2022 FY | 12.8 Billion KRW | 22.12% |
| 2022 Q3 | -1.01 Billion KRW | -63.63% |
| 2022 Q4 | 2.64 Billion KRW | 358.86% |
| 2022 Q2 | -623.27 Million KRW | -122.18% |
| 2022 Q1 | 2.8 Billion KRW | 329.2% |
| 2021 Q1 | -1.24 Billion KRW | -36.18% |
| 2021 Q2 | -761.33 Million KRW | 39.06% |
| 2021 Q3 | -562.63 Million KRW | 26.1% |
| 2021 FY | 10.48 Billion KRW | -24.83% |
| 2021 Q4 | -1.22 Billion KRW | -117.9% |
| 2020 Q2 | -651.77 Million KRW | -32.39% |
| 2020 FY | 13.95 Billion KRW | 822.77% |
| 2020 Q4 | -917.37 Million KRW | -68.48% |
| 2020 Q3 | -544.49 Million KRW | 16.46% |
| 2020 Q1 | -492.31 Million KRW | -1816.59% |
| 2019 Q3 | -779.57 Million KRW | -294.28% |
| 2019 FY | -1.93 Billion KRW | -133.82% |
| 2019 Q2 | -197.72 Million KRW | 80.46% |
| 2019 Q1 | -1.01 Billion KRW | -400.37% |
| 2019 Q4 | 28.67 Million KRW | 103.68% |
| 2018 Q3 | -509.15 Million KRW | -126.14% |
| 2018 FY | -825.58 Million KRW | 43.36% |
| 2018 Q1 | -428.13 Million KRW | 21.1% |
| 2018 Q2 | -225.14 Million KRW | 47.41% |
| 2018 Q4 | 336.84 Million KRW | 166.16% |
| 2017 Q2 | -754.46 Million KRW | -3858.16% |
| 2017 Q3 | -141.43 Million KRW | 81.25% |
| 2017 FY | -1.45 Billion KRW | -489.24% |
| 2017 Q1 | -19.06 Million KRW | -104.24% |
| 2017 Q4 | -542.64 Million KRW | -283.66% |
| 2016 FY | -247.37 Million KRW | 71.45% |
| 2016 Q1 | -230.53 Million KRW | -184.14% |
| 2016 Q4 | 449.57 Million KRW | 200.11% |
| 2016 Q3 | -449.08 Million KRW | -2492.13% |
| 2016 Q2 | -17.32 Million KRW | 92.48% |
| 2015 Q2 | -397.74 Million KRW | -63.8% |
| 2015 Q3 | -499.72 Million KRW | -25.64% |
| 2015 FY | -866.3 Million KRW | 83.81% |
| 2015 Q4 | 273.98 Million KRW | 154.83% |
| 2015 Q1 | -242.82 Million KRW | 88.95% |
| 2014 Q2 | -900.36 Million KRW | 23.73% |
| 2014 Q3 | -1.07 Billion KRW | -19.36% |
| 2014 FY | -5.35 Billion KRW | 60.5% |
| 2014 Q1 | -1.18 Billion KRW | 81.99% |
| 2014 Q4 | -2.19 Billion KRW | -104.43% |
| 2013 Q4 | -6.55 Billion KRW | -352.06% |
| 2013 Q3 | -1.45 Billion KRW | 38.91% |
| 2013 FY | -13.55 Billion KRW | 17.34% |
| 2013 Q1 | -3.17 Billion KRW | 23.64% |
| 2013 Q2 | -2.37 Billion KRW | 25.14% |
| 2012 Q4 | -4.15 Billion KRW | -104.74% |
| 2012 Q1 | -1.92 Billion KRW | 0.0% |
| 2012 Q2 | -8.16 Billion KRW | -325.04% |
| 2012 Q3 | -2.02 Billion KRW | 75.15% |
| 2012 FY | -16.39 Billion KRW | -2097.08% |
| 2011 Q1 | 1.42 Billion KRW | 0.0% |
| 2011 Q2 | 710.35 Million KRW | -50.13% |
| 2011 Q3 | 48.45 Million KRW | -93.18% |
| 2011 FY | 820.86 Million KRW | -35.29% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q1 | 1 Billion KRW | -33.27% |
| 2010 FY | 1.26 Billion KRW | -68.2% |
| 2010 Q2 | 3.18 Billion KRW | 217.34% |
| 2009 FY | 3.98 Billion KRW | 196.25% |
| 2009 Q3 | - KRW | -100.0% |
| 2009 Q1 | 2.34 Billion KRW | 906.01% |
| 2009 Q2 | 1.94 Billion KRW | -17.07% |
| 2009 Q4 | 1.5 Billion KRW | 0.0% |
| 2008 Q4 | 233.11 Million KRW | 0.0% |
| 2008 Q3 | - KRW | 100.0% |
| 2008 FY | -4.14 Billion KRW | -138.49% |
| 2008 Q2 | -408.97 Million KRW | -3.07% |
| 2008 Q1 | -396.78 Million KRW | -226.87% |
| 2007 Q3 | -1.67 Billion KRW | -3994.66% |
| 2007 Q2 | -41 Million KRW | 77.68% |
| 2007 Q1 | -183.65 Million KRW | 0.0% |
| 2007 FY | -1.73 Billion KRW | 0.0% |
| 2007 Q4 | 312.75 Million KRW | 118.63% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 19288.804% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 190.984% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 12.081% |
| HANDOK Inc. | 12.57 Billion KRW | 656.095% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -3416.606% |
| Yuhan Corporation | 74.56 Billion KRW | 193.814% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 725.76% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | -287.697% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 131.105% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 2388.905% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 587.444% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 11828.703% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 7358.023% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 358.774% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 19288.804% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | -801.88% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 1834.178% |
| JW Holdings Corporation | 143.66 Billion KRW | 148.69% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | -30.95% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 128.366% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 169.738% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | -47.598% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 1109.831% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 1180.977% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 901.137% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 19288.804% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 243.436% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 152.434% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 169.738% |
| Yuhan Corporation | 74.56 Billion KRW | 193.814% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 434.368% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 2343.871% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 262.694% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 169.738% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 441.482% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 227.299% |
| CKD Bio Corp. | -20.15 Billion KRW | -247.105% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 317.016% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 376.461% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 315.066% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | -47.598% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 311.031% |
| Boryung Corporation | 68.26 Billion KRW | 202.466% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | -86.55% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 587.444% |
| JW Lifescience Corporation | 32.09 Billion KRW | 317.972% |